Atorvastatin and cardiovascular risk in the elderly – patient considerations
Subroto Acharjee, Francine K WeltyDivision of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USAAbstract: Elderly individuals are at increased risk of coronary heart disease (CHD) and account for a majority of CHD deaths. Several clinical trials have assessed the beneficial effects of...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9fd27da84614431285e0e32857df8064 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9fd27da84614431285e0e32857df8064 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9fd27da84614431285e0e32857df80642021-12-02T03:35:24ZAtorvastatin and cardiovascular risk in the elderly – patient considerations1178-1998https://doaj.org/article/9fd27da84614431285e0e32857df80642008-06-01T00:00:00Zhttps://www.dovepress.com/atorvastatin-and-cardiovascular-risk-in-the-elderly-ndash-patient-cons-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Subroto Acharjee, Francine K WeltyDivision of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USAAbstract: Elderly individuals are at increased risk of coronary heart disease (CHD) and account for a majority of CHD deaths. Several clinical trials have assessed the beneficial effects of statins in individuals with, or at risk of developing, CHD. These trials provide evidence that statins reduce risk and improve clinical outcomes even in older patients; however, statin therapy remains under-utilized among the aged. Atorvastatin has been widely investigated among the older subjects and has the greatest magnitude of favorable effects on clinical outcomes of CHD. The pharmacokinetic properties of atorvastatin allow it to be used every other day, a factor which may decrease adverse events and be especially important in the elderly. The purpose of this article is to review the evidence available from randomized clinical trials regarding the safety and efficacy of atorvastatin in primary and secondary prevention of CHD and stroke in older patients and to discuss issues such as drug interactions, patient compliance and cost-effectiveness, which affect prescription of lipid-lowering therapy among older patients.Keywords: atorvastatin, statins, HMG-CoA reductase inhibitors, coronary heart disease, elderly patientsSubroto AcharjeeFrancine K WeltyDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 3, Pp 299-314 (2008) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Geriatrics RC952-954.6 |
| spellingShingle |
Geriatrics RC952-954.6 Subroto Acharjee Francine K Welty Atorvastatin and cardiovascular risk in the elderly – patient considerations |
| description |
Subroto Acharjee, Francine K WeltyDivision of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USAAbstract: Elderly individuals are at increased risk of coronary heart disease (CHD) and account for a majority of CHD deaths. Several clinical trials have assessed the beneficial effects of statins in individuals with, or at risk of developing, CHD. These trials provide evidence that statins reduce risk and improve clinical outcomes even in older patients; however, statin therapy remains under-utilized among the aged. Atorvastatin has been widely investigated among the older subjects and has the greatest magnitude of favorable effects on clinical outcomes of CHD. The pharmacokinetic properties of atorvastatin allow it to be used every other day, a factor which may decrease adverse events and be especially important in the elderly. The purpose of this article is to review the evidence available from randomized clinical trials regarding the safety and efficacy of atorvastatin in primary and secondary prevention of CHD and stroke in older patients and to discuss issues such as drug interactions, patient compliance and cost-effectiveness, which affect prescription of lipid-lowering therapy among older patients.Keywords: atorvastatin, statins, HMG-CoA reductase inhibitors, coronary heart disease, elderly patients |
| format |
article |
| author |
Subroto Acharjee Francine K Welty |
| author_facet |
Subroto Acharjee Francine K Welty |
| author_sort |
Subroto Acharjee |
| title |
Atorvastatin and cardiovascular risk in the elderly – patient considerations |
| title_short |
Atorvastatin and cardiovascular risk in the elderly – patient considerations |
| title_full |
Atorvastatin and cardiovascular risk in the elderly – patient considerations |
| title_fullStr |
Atorvastatin and cardiovascular risk in the elderly – patient considerations |
| title_full_unstemmed |
Atorvastatin and cardiovascular risk in the elderly – patient considerations |
| title_sort |
atorvastatin and cardiovascular risk in the elderly – patient considerations |
| publisher |
Dove Medical Press |
| publishDate |
2008 |
| url |
https://doaj.org/article/9fd27da84614431285e0e32857df8064 |
| work_keys_str_mv |
AT subrotoacharjee atorvastatinandcardiovascularriskintheelderlyndashpatientconsiderations AT francinekwelty atorvastatinandcardiovascularriskintheelderlyndashpatientconsiderations |
| _version_ |
1718401747854032896 |